BioSpace News Archive

INmune Bio, Inc. is pleased to announce the Company’s Chief Scientific Officer Dr. Lowdell will be leading a workshop on the role of natural killer (NK) cells in the treatment of solid tumors.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data in 2nd line metastatic NSCLC from its Phase II TACTI-002 trial.

Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort four at 1,000mg (twenty-fold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among 10 healthy male subjects.

Receptor Life Sciences Announces FDA Acceptance of IND Application for RLS103 (Inhaled Dry Powder CBD) and Initiation of IND-Opening Clinical Safety and Efficacy Study.

Remix Therapeutics today announced the publication of an article titled “Reprogramming RNA Processing: An Emerging Therapeutic Landscape,” in the peer-reviewed journal Trends in Pharmacological Sciences.

NeuroSense Therapeutics Ltd. today released a video presentation with a corporate update from its Founder and CEO Alon Ben-Noon.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO, has been invited to present at the 21st Annual Needham Virtual Healthcare Conference taking place from April 11 – 14.

ReAlta Life Sciences today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of RLS-0071 in neonates with hypoxic-ischemic encephalopathy (HIE).

ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2021.

NanoVibronix, Inc. today announced the Company’s PainGuard and UroGuard, offered as private label products through Ideal Medical International Limited, have been approved by Health Canada.